I have been interested in viruses since medical school and have structured the early stages of my clinical training in preparation for a career in infectious diseases. My research is focussed on viral genetics and evolution and how it can help us understand, treat and prevent diseases like viral hepatitis, zika and HIV. I believe that clinical microbial genetics will emerge as an important subspecialty to infectious diseases and as an important diagnostic service to other specialties that manage infectious pathologies.
I’m interested in microbial genetics, particularly of viruses. I work with a range of groups to develop methods for characterising and analysing viral genetic information using a range of next-generation sequencing methods and platforms. Most of the projects I work on are united by a clinical focus aimed at improving the effectiveness and efficiency of diagnosis and treatments in infectious diseases thus reducing some of the greatest burdens to global health
STOPHCV: STratified medicine to Optimise the treatment of Patients with hepatitis C virus (HCV) infection
PopART Phylogenetics : A phylogenetic study of HIV transmission (and how to prevent it) in a 10,000 infected indivuals living in Zambia
Oxford Viromics: Oxford Universities pipeline for sequencing and studying clinically relevant viral pathogens.
Genomic Epidemiology Reconstructs the Introduction and Spread of Zika Virus in Central America and Mexico.
Thézé J. et al, (2018), Cell Host Microbe, 23, 855 - 864.e7
Rolling circle amplification and nanopore-based deep sequencing of full-length HBV genomes
Mcnaughton A. et al, (2018), JOURNAL OF HEPATOLOGY, 68, S762 - S762
PHYLOSCANNER: Inferring Transmission from Within- and Between-Host Pathogen Genetic Diversity.
Wymant C. et al, (2018), Mol Biol Evol, 35, 719 - 733
Detection and Characterization of Homologues of Human Hepatitis Viruses and Pegiviruses in Rodents and Bats in Vietnam.
Van Nguyen D. et al, (2018), Viruses, 10
Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse.
Bonsall D. et al, (2018), Infect Drug Resist, 11, 1119 - 1135